{
  "docId": "019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "docSlug": "fef1528177829f37cded553f72a56b72",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 44,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a split-screen comparison of two distinct clinical trial datasets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ec7b-760b-b9a4-60ceb97e90d9/23",
  "deckHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "deckJsonHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9.json",
  "deckAnchorHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Farxiga CV death or worsening HF (full population)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e01380a-8502-41c5-bd39-15097fdff3c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.32,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "chart",
      "text": "eplontersen ATTRv-PN (NEURO-TTRansform)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c712f19a-d382-48b0-950f-7db1d65354e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.035,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "ESC = European Society of Cardiology; ISA = International Symposium of Amyloidosis; HFpEF = heart failure with preserved ejection fraction; CV = cardiovascular; HF = heart failure; ATTRv-PN = TTR-mediated amyloid polyneuropathy; LSM = least-square means; TTR = transthyretin. Collaboration partners: Ionis Pharmaceuticals Inc. (eplontersen).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41d5dd51-e75c-4f94-9ac2-0a8b4464e145",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.68
      },
      "kind": "list",
      "text": "Phase III 35-week interim analysis; 81.2% reduction in serum TTR concentration vs. baseline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5177e20d-2397-4c02-a447-e74d66ae84d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.04,
        "y": 0.68
      },
      "kind": "list",
      "text": "18% reduction in CV death in HF patients, with preserved ejection fraction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f592dbfe-a8aa-4aa3-a3c0-b4f2a6258a96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.43,
        "x": 0.035,
        "y": 0.13
      },
      "kind": "title",
      "text": "Showcasing strength at ESC and ISA",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a15b0d55-49d8-43ad-8831-8fcafa1c8d50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.56,
        "x": 0.035,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cecb2f4f-4abc-4961-bd4c-04ee181a30d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "f4ed89e4-c1df-492d-8c68-d2087961f24c",
      "evidence": "chart/line: Farxiga CV death or worsening HF (full population)",
      "confidence": 0.5
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f6e34c73-dafb-46f5-95b4-78d15f15c23e",
      "evidence": "list/bullet: Phase III 35-week interim analysis; 81.2% reduction in serum TTR concentration vs. baseline",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}